What is the role of procalcitonin (PCT) and C-reactive protein (CRP) levels in the evaluation for community-acquired pneumonia (CAP)?

1. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015 Jul 30. 373 (5):415-27. [Medline].

2. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014 Oct 23. 371 (17):1619-28. [Medline].

3. Cunha BA. Swine Influenza (H1N1) Pneumonia: Clinical Considerations. Infect Dis Clin N Am. 2010. 24:203-228.

4. [Guideline] Wunderink RG. Guidelines to Manage Community-Acquired Pneumonia. Clin Chest Med. 2018 Dec. 39 (4):723-731. [Medline].

5. Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017 Jul 10. 358:j2471. [Medline].

6. Huijskens EG, Koopmans M, Palmen FM, van Erkel AJ, Mulder PG, Rossen JW. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. J Med Microbiol. 2014 Mar. 63 (Pt 3):441-52. [Medline].

7. [Guideline] Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1. 200 (7):e45-e67. [Medline].

8. Boersma WG, Daniels JM, Löwenberg A, Boeve WJ, van de Jagt EJ. Reliability of radiographic findings and the relation to etiologic agents in community-acquired pneumonia. Respir Med. 2006 May. 100(5):926-32. [Medline].

9. Bruns AH, Oosterheert JJ, Prokop M, Lammers JW, Hak E, Hoepelman AI. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis. 2007 Oct 15. 45(8):983-91. [Medline].

10. Liu JL, Xu F, Hui Zhou, Wu XJ, Shi LX, Lu RQ, et al. Expanded CURB-65: a new score system predicts severity of community-acquired pneumonia with superior efficiency. Sci Rep. 2016 Mar 18. 6:22911. [Medline].

11. Sungurlu S, Balk RA. The Role of Biomarkers in the Diagnosis and Management of Pneumonia. Clin Chest Med. 2018 Dec. 39 (4):691-701. [Medline].

12. Kim MW, Lim JY, Oh SH. Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia. Scand J Clin Lab Invest. 2017 Nov. 77 (7):486-492. [Medline].

13. Savvateeva EN, Rubina AY, Gryadunov DA. Biomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management. Biomed Res Int. 2019. 2019:1701276. [Medline].

14. Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia. Respir Res. 2018 Oct 1. 19 (1):193. [Medline].

15. Kim B, Kim J, Jo YH, Lee JH, Hwang JE, Park MJ, et al. Prognostic value of pneumococcal urinary antigen test in community-acquired pneumonia. PLoS One. 2018. 13 (7):e0200620. [Medline].

16. Lin FM, Feng JY, Fang WF, Wu CL, Yu CJ, Lin MC, et al. Impact of prior pulmonary tuberculosis in treatment outcomes of HCAP and CAP patients in intensive care units. J Microbiol Immunol Infect. 2019 Apr. 52 (2):320-328. [Medline].

17. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin Allergy: A Review. JAMA. 2019 Jan 15. 321 (2):188-199. [Medline].

18. FDA. FDA Drug Safety Communication: FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. FDA. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-antibacterial-doribax-doripenem-describing. February 26, 2018; Accessed: July 2019.

19. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014 Feb 6. 370 (6):543-51. [Medline].

20. Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int J Antimicrob Agents. 2005 Dec. 26 Suppl 3:S148-55. [Medline].

21. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004 Apr. 20(4):555-63. [Medline].

22. Harrington Z, Barnes DJ. One drug or two? Step-down therapy after i.v. antibiotics for community-acquired pneumonia. Intern Med J. 2007 Nov. 37(11):767-71. [Medline].

23. Scalera NM, File TM Jr. How long should we treat community-acquired pneumonia?. Curr Opin Infect Dis. 2007 Apr. 20(2):177-81. [Medline].

24. Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S, et al. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2010 Jul. 36(1):128-34. [Medline].

25. [Guideline] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1. 44 Suppl 2:S27-72. [Medline].

26. Alvarez-Lerma F, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care. 2004 Oct. 10(5):369-74. [Medline].

27. Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med. 2009 Dec. 37(12):3010-6. [Medline]. [Full Text].

28. Carron M, Freo U, Zorzi M, Ori C. Predictors of failure of noninvasive ventilation in patients with severe community-acquired pneumonia. J Crit Care. 2010 Sep. 25(3):540.e9-14. [Medline].

29. Cunha BA. Severe Community-acquired Pneumoniae in the Critical Care Unit. Cunha BA (ed). Infectious Disease in Critical Care Medicine. 3rd Ed. New York, New York: Informa Healthcare; 2010. pp. 164-177.

30. Cilli A, Cakin O, Aksoy E, Kargin F, Adiguzel N, Karakurt Z, et al. Acute cardiac events in severe community-acquired pneumonia: A multicenter study. Clin Respir J. 2018 Jul. 12 (7):2212-2219. [Medline].

31. Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Anzueto A, Babu BL, et al. Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. Am J Respir Crit Care Med. 2017 Sep 1. 196 (5):609-620. [Medline].

32. Perry TW, Pugh MJ, Waterer GW, Nakashima B, Orihuela CJ, Copeland LA, et al. Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med. 2011 Mar. 124 (3):244-51. [Medline].

33. Postma DF, Spitoni C, van Werkhoven CH, van Elden LJR, Oosterheert JJ, Bonten MJM. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. BMC Infect Dis. 2019 Jan 7. 19 (1):17. [Medline].

34. Nakanishi M, Yoshida Y, Takeda N, Hirana H, Horita T, Shimizu K, et al. Significance of the progression of respiratory symptoms for predicting community-acquired pneumonia in general practice. Respirology. 2010 Aug. 15(6):969-74. [Medline].

35. Holter JC, Müller F, Bjørang O, Samdal HH, Marthinsen JB, Jenum PA, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis. 2015 Feb 15. 15:64. [Medline].

36. Musher DM, Abers MS, Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis. 2017 Oct 30. 65 (10):1736-1744. [Medline].

37. Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect. 2005 Feb. 50(2):107-13. [Medline].

38. Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis. 2016 Aug 1. 63 (3):300-9. [Medline].

39. Cilloniz C, Ewig S, Ferrer M, et al. Community acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care. 2011 Sep 14. 15(5):R209. [Medline].

40. Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016 Jun. 25 (140):178-88. [Medline].

41. Lim YK, Kweon OJ, Kim HR, Kim TH, Lee MK. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis. 2019 May. 94 (1):50-54. [Medline].

42. Burillo A, Bouza E. Chlamydophila pneumoniae. Infect Dis Clin North Am. 2010 Mar. 24(1):61-71. [Medline].

43. Heron M. Deaths: Leading Causes for 2015. National Vital Statistics Reports. Available at https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_05.pdf. November 27, 2017; Accessed: September 2019.

44. Brown JD, Harnett J, Chambers R, Sato R. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr. 2018 Apr 16. 18 (1):92. [Medline].

45. Teramoto S, Yamamoto H, Yamaguchi Y, Hanaoka Y, Ishii M, Hibi S, et al. Lower respiratory tract infection outcomes are predicted better by an age >80 years than by CURB-65. Eur Respir J. 2008 Feb. 31 (2):477-8; author reply 478. [Medline].

46. Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med. 2005 Jan. 99(1):60-5. [Medline].

47. Falguera M, Pifarre R, Martin A, Sheikh A, Moreno A. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest. 2005 Nov. 128(5):3233-9. [Medline].

48. Baum S. Mycoplasma pneumoniae and atypical pneumonia. Mandell, Bennett, & Dolin, eds. Principles and Practice of Infectious Diseases. 7th ed. Churchill Livingstone; 2010. Chapter 185.

49. Cunha BA, Burillo A, Bouza E. Legionnaires' disease. Lancet. 2016 Jan 23. 387 (10016):376-85. [Medline].

50. Anderson A, Bijlmer H, Fournier PE, Graves S, Hartzell J, Kersh GJ, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep. 2013 Mar 29. 62 (RR-03):1-30. [Medline].

51. Marrie TJ, Raoult D. Coxiella burnetti (Q fever). Mandell G, BennettJ, Dolin R, eds. PPID. 7th ed. Churchill Livingstone; 2009. Chapter 189.

52. Johansson N, Vondracek M, Backman-Johansson C, Sköld MC, Andersson-Ydsten K, Hedlund J. The bacteriology in adult patients with pneumonia and parapneumonic effusions: increased yield with DNA sequencing method. Eur J Clin Microbiol Infect Dis. 2019 Feb. 38 (2):297-304. [Medline].

53. Méndez R, Menéndez R, Cillóniz C, Amara-Elori I, Amaro R, González P, et al. Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. Am J Respir Crit Care Med. 2018 Aug 1. 198 (3):370-378. [Medline].

54. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018 Jan. 18 (1):95-107. [Medline].

55. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1. 63 (5):e61-e111. [Medline].

56. Loens K, Ieven M. Mycoplasma pneumoniae: Current Knowledge on Nucleic Acid Amplification Techniques and Serological Diagnostics. Front Microbiol. 2016. 7:448. [Medline].

57. Harris AM, Beekmann SE, Polgreen PM, Moore MR. Rapid urine antigen testing for Streptococcus pneumoniae in adults with community-acquired pneumonia: clinical use and barriers. Diagn Microbiol Infect Dis. 2014 Aug. 79 (4):454-7. [Medline].

58. Wunderink RG, Self WH, Anderson EJ, Balk R, Fakhran S, Courtney DM, et al. Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays. Clin Infect Dis. 2018 May 2. 66 (10):1504-1510. [Medline].

59. Cillóniz C, Torres A, Niederman M, van der Eerden M, Chalmers J, Welte T, et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med. 2016 Sep. 42 (9):1374-86. [Medline].

60. Waterer GW. Diagnosing Viral and Atypical Pathogens in the Setting of Community-Acquired Pneumonia. Clin Chest Med. 2017 Mar. 38 (1):21-28. [Medline].

61. Kuypers J. Impact of Rapid Molecular Detection of Respiratory Viruses on Clinical Outcomes and Patient Management. J Clin Microbiol. 2019 Apr. 57 (4):[Medline].

62. Huijskens EG, Rossen JW, Kluytmans JA, van der Zanden AG, Koopmans M. Evaluation of yield of currently available diagnostics by sample type to optimize detection of respiratory pathogens in patients with a community-acquired pneumonia. Influenza Other Respir Viruses. 2014 Mar. 8 (2):243-9. [Medline].

63. Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis. 2016 Apr 1. 62 (7):817-23. [Medline].

64. Davydov L, Ebert SC, Restino M, Gardner M, Bedenkop G, Uchida KM. Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. Diagn Microbiol Infect Dis. 2006 Apr. 54(4):267-75. [Medline].

65. Fishbane S, Niederman MS, Daly C, Magin A, Kawabata M, de Corla-Souza A. The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. Arch Intern Med. 2007 Aug 13-27. 167(15):1664-9. [Medline].

66. Marrie TJ, Huang JQ. Low-risk patients admitted with community-acquired pneumonia. Am J Med. 2005 Dec. 118(12):1357-63. [Medline].

67. Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore). 2007 Mar. 86(2):103-11. [Medline].

68. Yoshimoto A, Nakamura H, Fujimura M, Nakao S. Severe community-acquired pneumonia in an intensive care unit: risk factors for mortality. Intern Med. 2005 Jul. 44(7):710-6. [Medline].

69. Genné D, Sommer R, Kaiser L, Saaïdia A, Pasche A, Unger PF. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2006 Mar. 25(3):159-66. [Medline].

70. Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014 Dec. 174 (12):1894-901. [Medline].

71. Nuzyra (omadacycline) [package insert]. Boston, MA: Paratek Pharmaceuticals, Inc. 2018 October. Available at [Full Text].

72. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med. 2019 Feb 7. 380 (6):517-527. [Medline].

73. File TM Jr, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial. Clin Infect Dis. 2019 Feb 4. [Medline].

74. File TM Jr, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, et al. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Clin Infect Dis. 2016 Oct 15. 63 (8):1007-1016. [Medline].

75. Zhong NS, Sun T, Zhuo C, D'Souza G, Lee SH, Lan NH, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015 Feb. 15 (2):161-71. [Medline].

76. Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011 Apr. 66 Suppl 3:iii33-44. [Medline].

77. Chang SP, Lee HZ, Lai CC, Tang HJ. The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019. 12:433-438. [Medline].

78. U.S. National Library of Medicine. Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia (DEFINE-CABP). Clinicaltrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT02679573?term=delafloxacin&cond=Pneumonia&rank=1. July 29, 2019; Accessed: September 2019.

79. Baxdela (delafloxacin) [package insert]. Lincolnshire, Il: Melinta Therapeutics, Inc. October 2019. Available at [Full Text].

80. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6. 379 (10):913-923. [Medline].

81. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 Oct 6. 163 (7):519-28. [Medline].

82. Restrepo MI, Anzueto A, Torres A. Corticosteroids for Severe Community-Acquired Pneumonia: Time to Change Clinical Practice. Ann Intern Med. 2015 Oct 6. 163 (7):560-1. [Medline].

83. An MM, Zou Z, Shen H, Gao PH, Cao YB, Jiang YY. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010 Jul. 36(1):58-65. [Medline].

84. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006 Jan 1. 42(1):73-81. [Medline].

85. Davis SL, Delgado G Jr, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis. 2005 Jul 15. 41 Suppl 2:S136-43. [Medline].

86. Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz P,. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis. 2005 Dec 15. 41(12):1697-705. [Medline].

87. Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010 Jan. 123(1):47-53. [Medline].

88. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009 May 27. 301(20):2120-8. [Medline].

89. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010 Aug. 19(8):792-802. [Medline].

90. Restrepo MI, Mortensen EM, Anzueto A. Common medications that increase the risk for developing community-acquired pneumonia. Curr Opin Infect Dis. 2010 Apr. 23(2):145-51. [Medline].

91. Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016 Nov 15. 355:i5813. [Medline].

92. Ro Y, Eun CS, Kim HS, Kim JY, Byun YJ, Yoo KS, et al. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. Gut Liver. 2016 Jul 15. 10 (4):581-6. [Medline].

93. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009 Oct 7. CD002109. [Medline].

94. Carrie AG, Kozyrskyj AL. Outpatient treatment of community-acquired pneumonia: evolving trends and a focus on fluoroquinolones. Can J Clin Pharmacol. 2006. 13(1):e102-11. [Medline].

95. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med. 2005 Jul. 118 Suppl 7A:21S-28S. [Medline].

96. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19. 372 (12):1114-25. [Medline].

97. Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older--United States, 2016. MMWR Morb Mortal Wkly Rep. 2016 Feb 5. 65 (4):88-90. [Medline].

98. Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, Griffin MR. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. Clin Infect Dis. 2013 Jun. 56 (12):1774-7. [Medline].

99. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011 Jul. 32 (14):1730-5. [Medline].

100. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23. 310 (16):1711-20. [Medline].

101. Powner J, Gallaher T, Colombo R, Baer S, Huber L, Kheda M, et al. Influenza vaccination reduced pneumococcal disease in incident dialysis patients. American Society of Nephrology. 2014.

102. CDC. Flu Vaccine and People With Allergies. CDC. Available at https://www.cdc.gov/flu/prevent/egg-allergies.htm. December 28, 2017; Accessed: September 2019.

103. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015 Aug 7. 64 (30):818-25. [Medline].

104. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015 Sep 4. 64 (34):944-7. [Medline].

105. Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018 Apr. 12 (4):1320-1360. [Medline].

106. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014 Jun 4. 311(21):2199-208. [Medline].

107. Busko M. Azithromycin Benefits Outweigh MI Risks in Older Pneumonia Patients. Medscape Medical News. Available at http://www.medscape.com/viewarticle/826175. Accessed: June 9, 2014.

108. Cunha BA. Elevated Serum Transaminases in Mycoplasma pneumoniae Pneumonia. Clin Microbiol Infect. 2005. 11:1051-1054.

109. Cunha BA. Hypophosphatemia: Diagnostic Significance in Legionnaires' Disease. Am J Med. 2006. 119:5-6.

110. Bradley, JS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011. 53:e25-e76.

111. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Saux MC, Chassard D. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med. 2005 Jan. 33(1):104-9. [Medline].

112. Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther. 2010 Apr. 35(2):195-200. [Medline].

113. Noreddin AM, Elkhatib WF. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2010 May. 8(5):505-14. [Medline].

114. Cunha BA (ed). Pneumonia Essentials. 3rd Ed. Sudbury, MA: Jones & Bartlett; 2010.

115. Boulware DR, Daley CL, Merrifield C, Hopewell PC, Janoff EN. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. J Infect. 2007 Oct. 55(4):300-9. [Medline].

116. Westley BP, Chan PA. Questions remain regarding mandatory use of macrolides in community-acquired pneumonia. Intensive Care Med. 2010 Oct. 36(10):1787; author reply 1789-90. [Medline].

117. Iannini PB, Paladino JA, Lavin B, Singer ME, Schentag JJ. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother. 2007 Oct. 19(5):536-45. [Medline].

118. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007 Nov. 51(11):3977-82. [Medline].

119. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007 Oct 8. 167(18):1938-43. [Medline].

120. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged =65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014 Sep 19. 63(37):822-5. [Medline]. [Full Text].

121. Bonten M, Bolkenbaas M, Huijts S, et al. Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Abstract no. 0541. Pneumonia 2014;3:95. Available at https://pneumonia.org.au/public/journals/22/PublicFolder/ABSTRACTBOOKMASTERforwebupdated20-3-14.pdf.

122. Boggs W. Narrow-Spectrum Antibiotics Effective as Empiric Therapy for Pediatric Pneumonia. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/818253. Accessed: January 5, 2014.

123. Queen MA, Myers AL, Hall M, Shah SS, Williams DJ, Auger KA, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics. 2014 Jan. 133(1):e23-9. [Medline].

124. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J. 2006 Aug. 28(2):346-51. [Medline].

125. Athlin S, Lidman C, Lundqvist A, Naucler P, Nilsson AC, Spindler C, et al. Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. Infect Dis (Lond). 2018 Apr. 50 (4):247-272. [Medline].

Stephanie L Baer, MD Associate Professor of Medicine, Division of Infectious Diseases, Department of Medicine, Medical College of Georgia at Augusta University; Hospital Epidemiologist, VA Augusta Medical Center

Stephanie L Baer, MD is a member of the following medical societies: American Federation for Medical Research, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Rhonda E Colombo, MD, MHS, FACP, FIDSA Clinical Research Physician, Henry M Jackson Foundation (HJF) for the Advancement of Military Medicine, In Support of Infectious Disease Clinical Research Program (IDCRP), Associate Professor, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences

Rhonda E Colombo, MD, MHS, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, Infectious Diseases Society of America, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Charles V Sanders, MD Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine in New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center

Charles V Sanders, MD is a member of the following medical societies: Alliance for the Prudent Use of Antibiotics, Alpha Omega Alpha, American Association for Physician Leadership, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, American College of Physicians, American Federation for Medical Research, American Geriatrics Society, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association for Professionals in Infection Control and Epidemiology, Association of American Medical Colleges, Association of American Physicians, Association of Professors of Medicine, Infectious Disease Society for Obstetrics and Gynecology, Infectious Diseases Society of America, Louisiana State Medical Society, Orleans Parish Medical Society, Royal Society of Medicine, Sigma Xi, The Scientific Research Honor Society, Society of General Internal Medicine, Southeastern Clinical Club, Southern Medical Association, Southern Society for Clinical Investigation, Southwestern Association of Clinical Microbiology, The Foundation for AIDS Research

Disclosure: Receives royalties from Baxter International for: Takeda-receives royalties; UpToDate-receives royalties.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Fred A Lopez, MD Associate Professor and Vice Chair, Department of Medicine, Assistant Dean for Student Affairs, Louisiana State University School of Medicine

Fred A Lopez, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, Infectious Diseases Society of America, Louisiana State Medical Society

Disclosure: Nothing to disclose.

Jose A Vazquez, MD, FACP, FIDSA Chief, Division of Infectious Diseases, Professor, Department of Medicine, Medical College of Georgia at Augusta University

Jose A Vazquez, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Society for Microbiology, HIV Medicine Association, Immunocompromised Host Society, Infectious Diseases Society of America, International AIDS Society, International Immunocompromised Host Society, International Society for Human and Animal Mycology, International Society for Infectious Diseases, Medical Mycological Society of the Americas, Michigan Infectious Disease Society, Mycological Society of America, National Foundation for Infectious Diseases

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cidara; Amplyx; F2G<br/>Serve(d) as a speaker or a member of a speakers bureau for: Allergan; Astellas.

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.